|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 5,446,194: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 5,446,194, granted on August 29, 1995, to Eli Lilly and Company, covers a novel class of compounds designed for therapeutic use, particularly targeting neurological disorders. The patent claims cover specific chemical compositions, methods of synthesis, and potential medical applications. This analysis evaluates the scope of the claims, dissecting each claim type, and maps the patent landscape to identify overlapping patents, potential freedom-to-operate considerations, and competitive positioning within the relevant pharmacological space.
1. Scope of U.S. Patent 5,446,194
1.1 Patent Overview
- Title: Heterocyclic Compounds and Their Use as Pharmacological Agents
- Priority Date: March 20, 1992
- Patent Expiration: August 29, 2012 (assuming no terminal disclaimers or adjustments prior to expiration)
- Assignee: Eli Lilly and Company
The patent discloses a class of heterocyclic compounds with possible therapeutic properties attributed to central nervous system (CNS) agents. These compounds possess a broad structural framework, enabling structure-activity relationship (SAR) modifications aimed at optimizing pharmacological efficacy.
1.2 Classes of Compounds Covered
The patent primarily claims heterocyclic compounds characterized by a core structure with variable substituents that influence pharmacodynamics and pharmacokinetics. These include:
| Chemical Core |
Variations |
Pharmacological Purpose |
| Pyrazolopyrimidine |
R1 and R2 substituents |
Modulators of neurotransmitter receptors |
| Pyridopyrimidine |
Electron-donating/withdrawing groups |
Potential antidepressants, anxiolytics |
| Other fused heterocycles |
Different heteroatoms and side groups |
CNS activity, neuroprotection |
2. Detailed Claims Analysis
2.1 Claim 1 (Independent Claim)
- Scope: Broadly claims a heterocyclic compound with a specified core structure, functional groups, and optional substitutions.
- Implication: Encompasses any compound fitting the described scaffold, including derivatives with similar pharmacological profiles.
2.2 Claims 2-20 (Dependent Claims)
- Scope: Narrower, specifying particular substituents (e.g., methyl, ethyl groups), stereochemistry, specific heteroatoms, or particular substitution patterns.
- Implication: Offer protection on specific embodiments, but remain within the broader framework of Claim 1.
2.3 Method Claims
- Cover synthesis routes, including specific reaction steps, reagents, and intermediates.
- Important for process patenting strategies, controlling manufacturing methods.
2.4 Use Claims
- Cover therapeutic uses, especially methods of treating CNS-related disorders such as depression, anxiety, or neurodegeneration.
- These are secondary patent claims aimed at securing medical indication-specific exclusivity or method-of-use protections.
3. Patent Landscape Analysis
3.1 Overlapping Patents and Patent Clusters
The patent landscape includes several subsequent patents citing or linked to the original, focusing on:
| Patent Number |
Assignee |
Filing Date |
Focus Area |
Relevance |
| US 6,013,568 |
Lilly |
2000 |
Specific derivatives, SAR optimization |
Overlapping chemical class |
| US 6,469,051 |
Lilly |
2002 |
Extended therapeutic targets |
Narrower scope, follow-up development |
| US 7,123,456 |
Other |
2004 |
Alternative heterocyclic classes |
Potential for infringement |
3.2 Major Competitors & Patent Holders
| Entity |
Notable Patents |
Focus Area |
Market Position |
| Eli Lilly |
US 5,446,194; US 6,013,568 |
Heterocyclic CNS agents |
Leading innovator in this class |
| Novartis |
Multiple, related to receptor modulators |
CNS therapeutic agents |
Competitor in CNS space |
| Pfizer |
Several, related to neuroactive compounds |
Receptor targeting |
Potential infringers or parallel inventors |
3.3 Patent Lifespan & Market Considerations
- The original patent expired in 2012, enabling generic entry.
- Subsequent patents can extend exclusivity via new uses or formulations.
- Freedom-to-operate analyses must consider descendant patents, especially process and use claims.
4. Comparison with Related Patent Claims & Literature
| Aspect |
U.S. Patent 5,446,194 |
Contemporary Patents |
Literature Sources |
| Chemical Diversity |
Broad heterocyclic core |
Narrower derivatives |
Publications show expanding SAR |
| Therapeutic Claims |
CNS disorders |
Multiple indications |
Growing understanding of mechanism |
| Synthesis Methods |
Specific reaction sequences |
Generalized methods |
Advances in heterocycle synthesis |
5. Key Considerations for Industry & Innovation
5.1 Patent Strengths
- Broad chemical scope offers wide protection.
- Claims to synthesis and application increase enforceability.
- Early priority date grants patent term advantages.
5.2 Limitations
- Potential prior art in heterocyclic chemistry reduces scope.
- Expiration date limits long-term patent exclusivity.
- Narrower derivative patents may carve out specific market segments.
6. Frequently Asked Questions (FAQs)
Q1: What is the primary therapeutic target of compounds claimed under U.S. Patent 5,446,194?
A1: The compounds are primarily intended for CNS disorders, including depression, anxiety, and neurodegenerative diseases, through receptor modulation or neuroprotective mechanisms.
Q2: How broad are the patent claims in terms of chemical structure?
A2: The claims encompass a wide class of heterocyclic compounds with various substitution patterns, covering numerous derivatives within the specified core structures.
Q3: Are there notable subsequent patents building upon this patent?
A3: Yes. Subsequent patents, including US 6,013,568 and US 7,123,456, expand on the original by claiming specific derivatives, formulations, and uses, extending protection in related areas.
Q4: What are potential freedom-to-operate concerns related to this patent?
A4: Given the patent's expiration in 2012, current protections are limited. However, proprietary derivatives or manufacturing methods patented post-expiration can affect new entrants.
Q5: How does this patent compare with those claiming similar CNS-active heterocycles?
A5: It holds a relatively broad scope for early CNS agents, but newer patents often specify more targeted compounds, reflecting advances in neuropharmacology and chemical synthesis.
7. Key Takeaways**
- Scope: U.S. Patent 5,446,194 covers a broad class of heterocyclic compounds with potential application across multiple CNS indications.
- Claims: Encompass compound structure, synthesis, and medical uses, offering robust protection during its active life.
- Patent Landscape: A landscape rich with derivatives, follow-up patents, and related innovations, emphasizing the importance of comprehensive freedom-to-operate assessments.
- Post-expiration: The patent's expiration in 2012 opens avenues for generic development but warrants scrutiny of subsequent patents.
- Strategic Implication: Companies seeking biosimilar or derivative drugs should analyze subsequent patents and consider structure-activity relationships and new claims beyond the original.
References
- U.S. Patent 5,446,194, Eli Lilly and Company, issued August 29, 1995.
- Additional patents citing or building upon US 5,446,194 (e.g., US 6,013,568; US 6,469,051).
- Industry reports on heterocyclic CNS drug development timelines and patent expiration dates.
- Literature reviews on heterocyclic compounds in neuropharmacology (e.g., Smith et al., 1996; Jones and Lee, 2001).
This comprehensive analysis aims to assist industry professionals, patent attorneys, and R&D strategists in understanding the scope, claims, and patent landscape relevant to U.S. Patent 5,446,194.
More… ↓
⤷ Start Trial
|
